Psychemedics Corporation Announces Record First Quarter Revenues DECLARES 63rd CONSECUTIVE QUARTERLY DIVIDEND

ACTON, Mass., May 8, 2012 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD) today announced first quarter financial results for the period ended March 31, 2012.  The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of May 18, 2012 to be paid on May 31, 2012.  This will be the Company's 63rd consecutive quarterly dividend.

(Logo:  http://photos.prnewswire.com/prnh/20111107/NE00639LOGO )

The Company's revenue for the quarter ended March 31, 2012 was $6.2 million versus $6.0 million for the quarter ended March 31, 2011, an increase of 4%.  Net income for the quarter ended March 31, 2012 was $827 thousand or $0.16 per diluted share, versus $858 thousand or $0.16 per diluted share, for the comparable period last year.

Raymond C. Kubacki, Chairman and Chief Executive Officer, said,

"We are very pleased to report record sales for any first quarter in the Company's history. This is in comparison to our highest growth quarter last year.  While our base business experienced a moderate decrease in the quarter, new business was healthy and in fact, accounted for all the gain in the quarter.  We maintained tight cost control, but also continued to make investments in sales and marketing and in research and development. 

"We continue to have a strong balance sheet with more than $4.7 million in cash and cash equivalents as of March 31, 2012 and no long term debt.  

"Our directors share our confidence in the long-term future of Psychemedics and remain committed to rewarding shareholders and sharing the financial success of the Company with them as we move forward. 

"Therefore, the Board has declared a $0.15 dividend for the quarter. This is our 63rd consecutive quarterly dividend. In addition, we continue to have a share buyback program in place."

Psychemedics is the world's largest provider of hair testing for drugs of abuse with thousands of corporations relying on the proprietary Psychemedics drug testing services.  Psychemedics' clients include over 10% of the Fortune 500, some of the largest police departments in America and six Federal Reserve Banks.

The Psychemedics web site is www.psychemedics.com

Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995:  From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties.  In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning earnings, earnings per share, revenues, dividends, future business, growth opportunities, new accounts, customer base, market share, test volume and sales and marketing strategies) may be "forward looking" statements.  Actual results may differ from those stated in any forward-looking statements.  Factors that may cause such differences include but are not limited to risks associated with the expansion of the Company's sales and marketing team, development of markets for new products and services offered, the economic health of principal customers of the Company, government regulation, including but not limited to FDA regulations, competition and general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission.

Contact:                                                            

 Neil Lerner


Vice President of Finance


(978) 206-8220


Neill@psychemedics.com


 

 

PSYCHEMEDICS CORPORATION

STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

(UNAUDITED)






Three Months Ended


March 31,


2012


2011









Revenues

$6,243,855


$5,999,739

Cost of revenues

2,578,735


2,383,026





Gross profit

3,665,120


3,616,713









Operating Expenses:




   General & administrative

995,441


970,064

   Marketing & selling

1,124,825


1,014,117

   Research & development

168,048


142,451





Total Operating Expenses

2,288,314


2,126,632





Operating income

1,376,806


1,490,081

Interest income

510


2,205





Net income before provision for income taxes

1,377,316


1,492,286





Provision for income taxes

549,825


633,798





Net income and comprehensive income

$827,491


$858,488





Basic net income per share

$0.16


$0.16





Diluted net income per share

$0.16


$0.16





Dividends declared per share

$0.15


$0.12





Weighted average common shares outstanding, basic

5,235,422


5,212,013





Weighted average common shares outstanding, diluted

5,244,042


5,242,518









 

 

PSYCHEMEDICS CORPORATION

BALANCE SHEETS

(UNAUDITED)






March 31,


December 31,


2012


2011





ASSETS




 Current Assets:




   Cash and cash equivalents

$4,725,808


$5,564,233

   Accounts receivable, net of allowance for doubtful accounts




       of $150,974 in 2012 and $169,191 in 2011

4,799,119


4,490,976

   Prepaid expenses and other current assets

692,937


565,508

   Income tax receivable

52,136


564,083

   Deferred tax assets  

361,424


315,501





Total Current Assets

10,631,424


11,500,301





Fixed Assets:




   Equipment & leasehold improvements

13,287,885


13,089,655

   Less accumulated depreciation

(11,160,563)


(11,026,278)





Net Fixed Assets

2,127,322


2,063,377





   Other assets

256,213


237,174





Total Assets

$ 13,014,959


$  13,800,852





LIABILITIES AND SHAREHOLDERS' EQUITY








Current Liabilities:




   Accounts payable

$600,257


$961,844

   Accrued expenses

741,703


1,321,856





Total Current Liabilities

1,341,960


2,283,700





   Deferred tax liabilities, long-term

482,523


482,523

Total Liabilities

1,824,483


2,766,223





Shareholders' Equity:




   Preferred-stock, $0.005 par value, 872,521 shares authorized,




        no shares issued or outstanding

--


--

   Common stock, $0.005 par value; 50,000,000 shares authorized




       5,903,552 shares issued in 2012 and 2011

29,518


29,518

   Additional paid-in capital

28,209,615


28,095,946

   Accumulated deficit

(6,966,868)


(7,009,046)

   Less - Treasury stock, at cost, 668,130 shares in 2012 and 2011

(10,081,789)


(10,081,789)





Total Shareholders' Equity

11,190,476


11,034,629





Total Liabilities and Shareholders' Equity

$13,014,959


$13,800,852





SOURCE Psychemedics Corporation



RELATED LINKS
http://www.psychemedics.com

More by this Source

Best of Content We Love 2014 


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.